CareDx (CDNA) Tops Q2 EPS by 14c ; Offers Guidance

CareDx (NASDAQ: CDNA) reported Q2 EPS of $0.37, $0.14 better than the analyst estimate of $0.23. Revenue for the quarter came in at $132 million versus the consensus estimate of $113.82 million.

GUIDANCE:

CareDx sees FY2026 revenue of $490-500 million, versus the consensus of $455.9 million.

For earnings history and earnings-related data on CareDx (CDNA) click here.

You May Also Be Interested In

• Cencora says Walgreens volumes shift, reaffirms guidance, shares sink
• Onconetix (ONCO) files for up to 100M share offering by selling stockholders
• Citi raises Huya price target to $4.60 from $4.40